Ms. Joyce Margaret Stuart, RN, MS, BC Registered Nurse - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 6901 S Van Dorn St, Kingstowne, VA 22315 Phone: 703-313-6300 Fax: 703-313-6374 |
Ms. Cheryll Lynn Zellmer, RN Registered Nurse - Addiction (Substance Use Disorder) Medicare: Not Enrolled in Medicare Practice Location: 6901 S Van Dorn St, Kingstowne, VA 22315 Phone: 703-313-6300 Fax: 703-313-6374 |
Ms. Nadine Lynell Eads, RN Registered Nurse - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 6901 S Van Dorn St, Kingstowne, VA 22315 Phone: 703-313-6300 |
News Archive
Researchers from Polytechnique Montréal, Université de Montréal and McGill University have just achieved a spectacular breakthrough in cancer research.
EpiCept Corporation today announced that it has reached an agreement on all outstanding issues with the U.S. Food and Drug Administration (FDA) on a regulatory path forward for Ceplene® (histamine dihydrochloride), the Company's lead product for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first complete remission. Ceplene® is approved in the European Union for this indication and is marketed there by Meda AB.
A virtual heart, developed at The University of Manchester, is revealing new information about one of the world's most common heart conditions.
Emisphere Technologies, Inc. and Novo Nordisk A/S today announced that they have entered into an exclusive Development and License Agreement to develop and commercialize oral formulations of Novo Nordisk's insulins, which have the potential of treating diabetes, using Emisphere's Eligen® Technology. This is the second license agreement between the two companies. The first agreement, for the development of oral formulations of GLP-1 receptor agonists, was signed in June 2008, with a potential drug currently in a Phase I clinical trial.
› Verified 6 days ago